HuGE Literature Finder
Records
1
-
30
| Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia. Hematology reports 2022 Aug 14 (3): 265-269. Santoro Marco, Accurso Vincenzo, Mancuso Salvatrice, Napolitano Mariasanta, Mattana Marta, Vajana Giorgia, Russello Federica, Siragusa Serg |
| Hematological relevance of JAK2 V617F and calreticulin mutations in Tunisian patients with essential thrombocythemia. Journal of clinical laboratory analysis 2022 Jun e24522. Abdelghani Maroua, Hammami Haifa, Zidi Wiem, Amouri Hassiba, Othmen Hind Ben Hadj, Farrah Ahlem, Menif Sam |
| The risk of thrombosis in essential thrombocythemia is associated with the type of CALR mutation: A multicentre collaborative study. European journal of haematology 2020 Dec . Pérez Encinas Manuel M, Sobas Marta, Gómez-Casares María Teresa, Abuin Blanco Aitor, Noya Pereira María Soledad, Raya José María, Andrade-Campos Marcio Miguel, Álvarez Larrán Alberto, Lewandowki K, Lukasz Szukalski, Hernández Boluda Juan Carlos, Ferrer-Marín Francisca, Fox María Laura, Golos Aleksandra, Gasior Kabat Mercedes, Magro Mazo Elena, Czyz Anna, Martín Martín Alejandro, Bellosillo Paricio Beatriz, Quinteiro García Celsa, González Martín Jesús María, Stuckey Ru |
| Next-generation sequencing in the diagnosis of non-cirrhotic splanchnic vein thrombosis. Journal of hepatology 2020 Jul . Magaz Marta, Alvarez-Larrán Alberto, Colomer Dolors, López-Guerra Mónica, García-Criado M Ángeles, Mezzano Gabriel, Belmonte Ernest, Olivas Pol, Soy Guillem, Cervantes Francisco, Darnell Anna, Ferrusquía-Acosta José, Baiges Anna, Turon Fanny, Hernández-Gea Virginia, García-Pagán Juan Carl |
| Thrombophilic Risk of Factor V Leiden, Prothrombin G20210A, MTHFR, and Calreticulin Mutations in Essential Thrombocythemia Egyptian Patients. Advances in hematology 2020 2020 7695129. El-Ghonemy Mohamed S, El Sharawy Solafa, Fahmi Maryan Waheeb, El-Ashwah Shaimaa, Denewer May, El-Baiomy M |
| Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors. Medical oncology (Northwood, London, England) 2018 Aug 35 (9): 119. Helbig Grzego |
| Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis. Thrombosis research 2018 May 167 96-103. Li Miaomiao, De Stefano Valerio, Song Tingxue, Zhou Xinmiao, Guo Zeqi, Zhu Jia, Qi Xingsh |
| Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study. Journal of hepatology 2017 May . Poisson Johanne, Plessier Aurélie, Kiladjian Jean-Jacques, Turon Fanny, Cassinat Bruno, Andreoli Annalisa, De Raucourt Emmanuelle, Goria Odile, Zekrini Kamal, Bureau Christophe, Lorre Florence, Cervantes Francisco, Colomer Dolors, Durand François, Garcia-Pagan Juan-Carlos, Casadevall Nicole, Valla Dominique-Charles, Rautou Pierre-Emmanuel, Marzac Christophe, |
| [Mutation of CALR Gene in Patients with Chronic Myeloproliferative Neoplasm and Its Clinical Significance]. Zhongguo shi yan xue ye xue za zhi 2017 Feb 25 (1): 151-156. Tang Qin, Zhang Xiu-Wen, Xia Lei, Jiang Nai- |
| Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. Journal of hematology & oncology 2017 Feb 10 (1): 54. Lussana Federico, Carobbio Alessandra, Salmoiraghi Silvia, Guglielmelli Paola, Vannucchi Alessandro Maria, Bottazzi Barbara, Leone Roberto, Mantovani Alberto, Barbui Tiziano, Rambaldi Alessand |
| Estimation of diagnosis and prognosis in ET by assessment of CALR and JAK2 mutations and laboratory findings: a meta-analysis. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2017 Feb . Saki N, Shirzad R, Rahim F, Saki Malehi |
| [Clinical features of essential thrombocythemia and primary myelofibrosis, depending on the molecular characteristics of disease]. Terapevticheskii arkhiv 2017 89 (7): 4-9. Melikyan A L, Subortseva I N, Sudarikov A B, Kovrigina A M, Gilyazitdinova E A, Kolosheinova T I, Abdullaev A O, Treglazova S |
| Re: Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Annals of hematology 2016 Sep . Kourie Hampig Raphael, Ameye Lieveke, Paesmans Marianne, Bron Dominiq |
| Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia. Oncotarget 2016 Jul . Min-Gu Kang, Hyun-Woo Choi, Jun Hyung Lee, Yong Jun Choi, Hyun-Jung Choi, Jong-Hee Shin, Soon-Pal Suh, Szardenings Michael, Hye-Ran Kim, Myung-Geun Sh |
| Prognostic value of CALR vs. JAK2V617F mutations on splenomegaly, leukemic transformation, thrombosis, and overall survival in patients with primary fibrosis: a meta-analysis. Annals of hematology 2016 Jul . Pei Yu-Qing, Wu Yue, Wang Fei, Cui W |
| Thrombotic risk correlates with mutational status in true essential thrombocythemia. European journal of clinical investigation 2016 Jun . Bertozzi I, Peroni E, Coltro G, Bogoni G, Cosi E, Santarossa C, Fabris F, Randi M |
| Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. American journal of hematology 2016 May 91 (5): 503-6. Elala Yoseph C, Lasho Terra L, Gangat Naseema, Finke Christy, Barraco Daniela, Haider Mahnur, Abou Hussein Ahmed K, Hanson Curtis A, Ketterling Rhett P, Pardanani Animesh, Tefferi Ayal |
| Molecular biomarkers of thrombosis in myeloproliferative neoplasms. Thrombosis research 2016 Apr 140 Suppl 1 S71-5. Barbui Tiziano, Falanga An |
| PO-19 - Platelet (PLT) adhesion under flow condition in essential thrombocythemia (ET) and polycythemia vera (PV) is variably influenced according to patient mutational status. Thrombosis research 2016 Apr 140 Suppl 1 S183. Vignoli A, Tessarolo S, Marchetti M, Gamba S, Piras F, Finazzi G, van der Meijden P E J, Swieringa F, Ten Cate H, Heemskerk J W M, Rambaldi A, Falanga |
| Improved Survival of Calreticulin-Mutated Patients Compared With Janus Kinase 2 in Primary Myelofibrosis: A Meta-Analysis. Clinical lymphoma, myeloma & leukemia 2016 Feb . Kourie Hampig Raphael, Ameye Lieveke, Paesmans Marianne, Bron Dominiq |
| Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia 2015 Oct . Pietra D, Rumi E, Ferretti V V, Di Buduo C A, Milanesi C, Cavalloni C, Sant'Antonio E, Abbonante V, Moccia F, Casetti I C, Bellini M, Renna M C, Roncoroni E, Fugazza E, Astori C, Boveri E, Rosti V, Barosi G, Balduini A, Cazzola |
| Genetic Risk Factors of Venous Thromboembolism in the East Algerian Population. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis 2015 Aug . Moussaoui S, Saussoy P, Ambroise J, Defour J P, Zouitene R, Sifi K, Abadi |
| JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis. Pathology oncology research : POR 2015 Jul 21 (3): 751-8. Pósfai Éva, Marton Imelda, Király Péter Attila, Kotosz Balázs, Kiss-László Zsuzsanna, Széll Márta, Borbényi Zi |
| Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. European journal of haematology 2015 Jun . Mela Osorio María J, Ferrari Luciana, Goette Nora P, Gutierrez Marina I, Glembotsky Ana C, Maldonado Ana C, Lev Paola R, Alvarez Clarisa, Korin Laura, Marta Rosana F, Molinas Felisa C, Heller Paula |
| Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia 2015 Jun 29 (6): 1344-9. Palandri F, Latagliata R, Polverelli N, Tieghi A, Crugnola M, Martino B, Perricone M, Breccia M, Ottaviani E, Testoni N, Merli F, Aversa F, Alimena G, Cavo M, Martinelli G, Catani L, Baccarani M, Vianelli |
| Discrepancies between bone marrow histopathology and clinical phenotype in BCR-ABL1-negative myeloproliferative neoplasms associated with splanchnic vein thrombosis. Leukemia research 2015 May 39 (5): 525-9. Gianelli Umberto, Iurlo Alessandra, Cattaneo Daniele, Bossi Anna, Cortinovis Ivan, Augello Claudia, Moro Alessia, Savi Federica, Castelli Roberto, Brambilla Cecilia, Bianchi Paola, Primignani Massimo, Cortelezzi Agostino, Bosari Silva |
| Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea. Annals of laboratory medicine 2015 Mar 35 (2): 233-7. Park Sang Hyuk, Kim Shine Young, Lee Sun Min, Yi Jongyoun, Kim In-Suk, Kim Hyung Hoi, Chang Chulhun Ludgerus, Lee Eun Yup, Song Moo-Kon, Shin Ho-Jin, Chung Joo Se |
| A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia. International journal of hematology 2015 Feb 101 (2): 165-72. Yang Yining, Wang Xiaorui, Wang Chun, Qin Youw |
| Role of calreticulin mutations in the aetiological diagnosis of splanchnic vein thrombosis. Journal of hepatology 2015 Jan 62 (1): 72-4. Turon Fanny, Cervantes Francisco, Colomer Dolors, Baiges Anna, Hernández-Gea Virginia, Garcia-Pagán Juan Carl |
| Clinical Manifestation of Calreticulin Gene Mutations in Essential Thrombocythemia without Janus Kinase 2 and MPL Mutations: A Chinese Cohort Clinical Study. Chinese medical journal 0 129 (15): 1778-1783. Sun Chao, Zhou Xin, Zou Zhi-Jian, Guo Hong-Feng, Li Jian-Yong, Qiao Ch |
- Page last reviewed:Jul 25, 2022
- Page last updated:Dec 02, 2022
- Content source: